Mesothelioma is very difficult to treat, partly because it is usually not detected until the disease has progressed to the last phase. If the disease has been detected earlier, patients with mesothelioma is a better result. Some researchers see a breakthrough in the detection of mesothelioma in the form of a blood test called MESOMARK. In MESOMARK test blood is taken from the patient and sent to a laboratory to measure the amount of a particular biomarker called EIA. Some EIA levels point to the presence of mesothelioma. Manufacturer suggests that early detection of biomarkers can in the blood of patients for early diagnosis of lead, leading to better treatment options and prognosis for the patient.
In addition to detecting the presence of mesothelioma patients who have not been diagnosed with the disease, blood MESOMARK is also in the monitoring of treatment response in patients who are diagnosed with mesothelioma have been useful. Blood tests could be to determine the future direction of treatment of these patients.
MESOMARK in Australia was launched in March 2005 and in Europe a few months later. The Food and Drug Administration approved blood test for humanitarian purposes in the United States alone in January 2007. The test was from Fujirebio Diagnostics Inc., Malvern, Pennsylvania developed.
Make you know about mesothelioma lawyers,asbestos lawyers and mesothelioma treatments knowledge
